Intracoronary Infusion of Encapsulated Glucagon-Like Peptide-1–Eluting Mesenchymal Stem Cells Preserves Left Ventricular Function in a Porcine Model of Acute Myocardial Infarction

Jong, Renate de; Hout, Gerardus P.J. van; Houtgraaf, Jaco H.; Kazemi, Kushan; Wallrapp, Christine; Lewis, Andrew L.; Pasterkamp, Gérard; Hoefer, Imo E.; Duckers, Henricus J.

doi:10.1161/circinterventions.114.001580

Cited by 30 publications

(35 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in a swine model of AMI, three doses of CellBeads™ (alginate-encapsulated MSCs) were analyzed, with the medium dose (20,000 beads, ca. 1.6 × 10 6 cells) being more efficient to recuperate LV structure and function [102]. In brief, after a particular stem cell therapy have shown potential in small animal studies we advise researchers to test more than two cell doses with swine models in order to maximize the outcome of the therapy by picking up the most effective dose to be further tested in clinical trials.…”

Section: Cell Choice Refinement Dosage and Timing Of Administrationmentioning

confidence: 99%

“…The majority of the investigations sought to enhance the expression of a certain gene [23,24,61,63,66,74,76,102,104,109,110,117] or to transfect cells with microRNAs (miRs) [16,19]. The only example of gene repression was reported by Wang et al [39], who described the silencing of prolyl hydroxylase domain protein 2 gene (PHD2) as an alternative combined genetic and cell therapy approach.…”

Section: Genetic Engineeringmentioning

confidence: 99%

“…connexin-43 overexpression [63]); stimulating angiogenesis (SVVYGLR peptide overexpression [66]) or simply by enhancing the positive paracrine growth factor-related stimulation (e.g. HGF [24], IGF-1 [61,117] or recombinant glucagon-like peptide-1 (GLP-1) overexpression [102,104]). Regardless of the strategy, it was constantly observed a better outcome in genetically modified stem cells in comparison to naïve cells in, at least, one criterion.…”

Section: Genetic Engineeringmentioning

confidence: 99%

“…immunogenic and oncogenic risk, which makes virus-mediated genetically-engineered stem cells not consensual in the scientific and medical community [19,23,39,61,66,74,102,104,110,117]. This matter can be easily overcome by developing safer transfection methods such as electroporation [76] or through the use of non-viral plasmids [63,109] or lipid-based transfection reagents [16].…”

Section: Genetic Engineeringmentioning

confidence: 99%

“…That is the rationale behind the use of multiple strategies in stem cell therapy investigations [60,66,102,104]. For example, Uchinaka and colleagues [66] tested the therapeutic potential of osteopontin-derived SV peptide (SVVYGLR)-transfected SKS in a rat model of CMI.…”

Section: Combined Strategiesmentioning

confidence: 99%

See 4 more Smart Citations

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Trindade

Leite‐Moreira

Ferreira-Martins

et al. 2017

International Journal of Cardiology

View full text Add to dashboard Cite

Today there is an increasing demand for heart transplantations for patients diagnosed with heart failure. Though, shortage of donors as well as the large number of ineligible patients hurdle such treatment option. This, in addition to the considerable number of transplant rejections, has driven the clinical research towards the field of regenerative medicine. Nonetheless, to date, several stem cell therapies tested in animal models fall by the wayside and when they meet the criteria to clinical trials, subjects often exhibit modest improvements. A main issue slowing down the admission of such therapies in the domain of human trials is the lack of protocol standardization between research groups, which hampers comparison between different approaches as well as the lack of thought regarding the clinical translation. In this sense, given the large amount of reports on stem cell therapy studies in animal models reported in the last 3 years, we sought to evaluate their advantages and limitations towards the clinical setting and provide some suggestions for the forthcoming investigations. We expect, with this review, to start a new paradigm on regenerative medicine, by evoking the debate on how to plan novel stem cell therapy studies with animal models in order to achieve more consistent scientific production and accelerate the admission of stem cell therapies in the clinical setting.

show abstract

Section: Cell Choice Refinement Dosage and Timing Of Administrationmentioning

confidence: 99%

Section: Genetic Engineeringmentioning

confidence: 99%

Section: Genetic Engineeringmentioning

confidence: 99%

Section: Genetic Engineeringmentioning

confidence: 99%

Section: Combined Strategiesmentioning

confidence: 99%

See 3 more Smart Citations

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Trindade

Leite‐Moreira

Ferreira-Martins

et al. 2017

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews

Fisher

Dorée

Taggart

et al. 2016

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Meta-analyses of cell therapy trials for heart disease have yielded discrepant results. To resolve limitations associated with meta-analyses, such as imprecision and accumulation of random errors, we conducted trial sequential analysis (TSA). Randomized controlled trials that administered autologous bone marrow-derived cells to patients who suffered acute myocardial infarction (AMI) or heart failure (HF) were included. TSA has been applied to two clinical outcomes, all-cause mortality and hospitalization for HF, and to left ventricular ejection fraction (LVEF), as a surrogate of heart function. The results suggest that there is evidence of reduction of the risk of mortality and hospitalization in HF, but insufficient evidence to determine treatment effect in AMI. Moreover, the treatment does not improve LVEF by more than a mean difference of 4% when administered to either AMI or HF patients. The required number of participants to include in a meta-analysis to detect treatment effect was also estimated.

show abstract

A canine acute coronary occlusion model using thrombus implantation by percutaneous coronary intervention

Ma,

Yang,

Zhang

et al. 2023

iRADIOLOGY

View full text Add to dashboard Cite

ObjectiveTo establish an acute canine coronary artery occlusion model by implanting a mixed thrombus prepared in vitro into the coronary artery by percutaneous coronary intervention (PCI).MethodsThis study included 14 healthy Beagle dogs aged 10–13 months. First, 5 ml of canine venous blood was drawn to prepare the coronary artery thrombus in vitro. The thrombus was then implanted into the canine coronary artery by PCI to establish an animal model of acute coronary artery occlusion. Dogs were randomly divided into two experimental groups: group A, in which dogs were assessed for 2 h after coronary occlusion, and group B, in which dogs were assessed for 4 h after surgery. Baseline and postoperative assessment included cardiac troponin T (cTnT) levels, electrocardiography (ECG), plain and contrast echocardiography, and large‐scale digital subtraction angiography (DSA).ResultsCanine venous blood was successfully used to prepare a mixed thrombus with reticular fibrin structure and activated platelets in vitro. After the mixed thrombus was implanted into the coronary artery, large‐scale DSA showed no contrast medium perfusion, confirming complete occlusion of the coronary artery. After the coronary artery occlusion, dogs in both groups showed ST segment elevation >0.5 MV, a 0.9 μg/L increase in CTnT (p < 0.001), and increased EDV and ESV. Dogs also showed decreased left ventricular EF and FS and decreased MBF in the infarcted area (p < 0.05).ConclusionsAn experimental model of acute coronary artery occlusion in dogs was successfully established by implanting a mixed thrombus developed in vitro into the coronary artery using minimally invasive PCI.

show abstract

Intracoronary Infusion of Encapsulated Glucagon-Like Peptide-1–Eluting Mesenchymal Stem Cells Preserves Left Ventricular Function in a Porcine Model of Acute Myocardial Infarction

Cited by 30 publications

References 47 publications

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews

A canine acute coronary occlusion model using thrombus implantation by percutaneous coronary intervention

Contact Info

Product

Resources

About